Cantargia Q3 2024 - IL1RAP Companion Diagnostic Next
Redeye comments on Cantargia’s Q3 report, the proposed rights issue of SEK170m and the plans to focus on IL1RAP-high patients.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/